Holy Stone Healthcare Co (ROCO:4194) ROCE %: -60.44% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4194 Holy Stone Healthcare Co Ltd ROCO:4194
41 GF Score
Price NT$6.99
GF Value NT$3.93
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Holy Stone Healthcare Co ROCE %?

Holy Stone Healthcare Co ROCO:4194 +4.33% 41 ROCE % is -60.44% as of Dec. 2025. GuruFocus rates ROCO:4194 with a GF Score™ of 41/100 and a GF Value™ of NT$3.93 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Holy Stone Healthcare Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -60.44%.

Holy Stone Healthcare Co  (ROCO:4194) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Holy Stone Healthcare Co ROCE % Related Terms

Holy Stone Healthcare Co ROCE % Historical Data

* Premium members only.

The historical data trend for Holy Stone Healthcare Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Holy Stone Healthcare Co ROCE % Chart

Holy Stone Healthcare Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.46 -35.43 -89.15 -91.46 -45.05

Holy Stone Healthcare Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -119.81 -70.03 -54.49 -30.82 -60.44
ROCO:4194
41GF Score
Holy Stone Healthcare Co Ltd ROCO:4194
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Holy Stone Healthcare Co ROCE % Calculation

Holy Stone Healthcare Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-111.062/( ( (352.988 - 49.278) + (220.518 - 31.191) )/ 2 )
=-111.062/( (303.71+189.327)/ 2 )
=-111.062/246.5185
=-45.05 %

Holy Stone Healthcare Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-135.438/( ( (288.939 - 30.075) + (220.518 - 31.191) )/ 2 )
=-135.438/( ( 258.864 + 189.327 )/ 2 )
=-135.438/224.0955
=-60.44 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -60.44% mean?
Holy Stone Healthcare Co (ROCO:4194) has a ROCE % of -60.44% as of Dec. 2025.
Is Holy Stone Healthcare Co's ROCE % too high?
Holy Stone Healthcare Co's current ROCE % is -60.44%. Overall, Holy Stone Healthcare Co has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Holy Stone Healthcare Co's ROCE % compare to VRTX and REGN?
Holy Stone Healthcare Co's ROCE % of -60.44% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Holy Stone Healthcare Co's current ROCE % is -60.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Holy Stone Healthcare Co stock overvalued right now?
Based on GuruFocus' analysis, Holy Stone Healthcare Co (ROCO:4194) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$3.93, compared to a current price of NT$6.99 — trading 77.9% above its estimated fair value. The current ROCE % is -60.44%. Holy Stone Healthcare Co's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Holy Stone Healthcare Co (ROCO:4194), the current ROCE % is -60.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Holy Stone Healthcare Co (ROCO:4194) Overvalued in 2026?

Based on GuruFocus' analysis, Holy Stone Healthcare Co stock appears to be overvalued. The current stock price of NT$6.99 is trading 77.9% above its estimated GF Value™ of NT$3.93. GuruFocus considers Holy Stone Healthcare Co to be Significantly Overvalued.

Key valuation signals for ROCO:4194:

  • ROCE %: -60.44%
  • GF Value™: NT$3.93 vs. price of NT$6.99 (77.9% above fair value)
  • GF Score™: 41/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4194 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Holy Stone Healthcare Co Business Description

Address Number 88, Section 1, Neihu Road, 4th Floor, Neihu District, Taipei, TWN, 11493
Holy Stone Healthcare Co Ltd is a Taiwan based company focused on a biopolymer drug delivery platform. It is involved in the development of new drugs and medical devices, especially hyaluronic acid related therapeutic products. The products of the company include RenehaVis, SportVis, TRUD, and GAF.
41GF Score

Get the complete analysis for ROCO:4194

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$6.99
Price
NT$3.93
GF Value